Moderna Legal Representative Participates in AI Governance Series
Henry Hagen from Moderna's legal department is participating in a new four-part AI governance series launched by the Practising Law Institute and the American Arbitration Association.
Stocks · News reference
Jefferies analyst Andrew Tsai has initiated coverage on Moderna (MRNA) with a 'Hold' rating and a price target of $215.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Henry Hagen from Moderna's legal department is participating in a new four-part AI governance series launched by the Practising Law Institute and the American Arbitration Association.
Both mRNA pioneers are transitioning beyond COVID-19 vaccine revenues. Moderna is recommended as the better buy due to growing sales, an advancing personalized cancer vaccine (intismeran) showing 42% risk reduction in melanoma trials, and an expanding vaccine portfolio. BioNTech, while having strong cash reserves and a promising pipeline, faces leadership transitions and more distant revenue opportunities.
Moderna officer Stephen Hoge sold 78,375 shares of common stock in mid-November 2026 for a total value of approximately $16.9 million.
Moderna Taiwan hosted its mRNA Innovation Awards, highlighting advancements in mRNA technology research.
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.